2073864-81-8: Elagolix Impurity 2
It is an impurity present in Elagolix, Elagolix is a gonadotropin-releasing hormone receptor antagonist that inhibits endogenous GnRH, By administration of elagolix shows results in dose-dependent suppression of luteinizing hormone and follicle-stimulating hormone, which leads to decreased blood concentrations of the ovarian sex hormones, estradiol, and progesterone, which is used to treat moderate to severe pain in endometriosis.
Additional information on CAS 2073864-81-8
VE006362
2073864-81-8
C31H28F5N3O3
585.6
Elagolix
(R)-5-(2-fluoro-3-methoxyphenyl)-1-(2-fluoro-6-(trifluoromethyl)benzyl)-6-methyl-3-(2-phenyl-2-(propan-2-ylideneamino)ethyl)pyrimidine-2, 4(1H, 3H)-dione
N/A
Archer, D. F., Soliman, A. M., Agarwal, S. K., & Taylor, H. S. (2020). Elagolix in the treatment of endometriosis: impact beyond pain symptoms. Therapeutic Advances in Reproductive Health, 14, 263349412096451. https://doi.org/10.1177/2633494120964517 Lamb, Yvette N. “Elagolix: First Global Approval.” Drugs, vol. 78, no. 14, Sept. 2018, pp. 1501–8, https://doi.org/10.1007/s40265-018-0977-4.
Under Development
